François Anna

3.1k total citations
18 papers, 352 citations indexed

About

François Anna is a scholar working on Immunology, Infectious Diseases and Genetics. According to data from OpenAlex, François Anna has authored 18 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Infectious Diseases and 5 papers in Genetics. Recurrent topics in François Anna's work include Immunotherapy and Immune Responses (8 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Virus-based gene therapy research (5 papers). François Anna is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Virus-based gene therapy research (5 papers). François Anna collaborates with scholars based in France and Italy. François Anna's co-authors include Julien Caumartin, Pierre Langlade‐Demoyen, Pierre Charneau, Maryline Bourgine, Philippe Souque, Laleh Majlessi, Robin Nesbitt, Clair Mills, Erica Simons and Thomas Roederer and has published in prestigious journals such as Frontiers in Immunology, Annals of the Rheumatic Diseases and Cell Reports.

In The Last Decade

François Anna

17 papers receiving 349 citations

Peers

François Anna

IMMUN

ONCOL

GENET

Xiang Guo China

Martina Trinkaus Canada

Beth K Thielen United States

Daniel A. Lichtenstein United States

Tina Thomson United Kingdom

Romain Marlin France

Estela Luz Brazil

Hashaam Akhtar Pakistan

Juliette Rochefort France

Sam M. Murray United Kingdom

Xiang Guo China

François Anna

116 ×0.8

183 ×1.4

IMMUN

55 ×0.8

ONCOL

57 ×1.0

14 ×0.3

GENET

Citations per year, relative to François Anna François Anna (= 1×) peers Xiang Guo

Countries citing papers authored by François Anna

Since Specialization

Citations

This map shows the geographic impact of François Anna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Anna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Anna more than expected).

Fields of papers citing papers by François Anna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Anna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Anna. The network helps show where François Anna may publish in the future.

Co-authorship network of co-authors of François Anna

This figure shows the co-authorship network connecting the top 25 collaborators of François Anna. A scholar is included among the top collaborators of François Anna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Anna. François Anna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Blanc, Catherine, et al.. (2025). Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity. npj Vaccines. 10(1). 143–143.

Douguet, Laëtitia, et al.. (2024). T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector. npj Vaccines. 9(1). 102–102. 1 indexed citations

Douguet, Laëtitia, Jodie Lopez, Fabien Névo, et al.. (2023). Full eradication of pre‐clinical human papilloma virus‐induced tumors by a lentiviral vaccine. EMBO Molecular Medicine. 15(10). e17723–e17723. 6 indexed citations

Nemirov, Kirill, et al.. (2023). Lentiviral Vectors as a Vaccine Platform against Infectious Diseases. Pharmaceutics. 15(3). 846–846. 19 indexed citations

Chardenoux, Sébastien, Maryline Bourgine, Kirill Nemirov, et al.. (2023). Mice humanized for MHC and hACE2 with high permissiveness to SARS-CoV-2 omicron replication. Microbes and Infection. 25(7). 105142–105142. 1 indexed citations

Lopez, Jodie, François Anna, Alexandre Pawlik, et al.. (2022). A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity. Cell Reports. 40(4). 111142–111142. 11 indexed citations

Blanc, Catherine, Kirill Nemirov, François Anna, et al.. (2022). Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters. Vaccines. 11(1). 12–12. 2 indexed citations

Anna, François, Jodie Lopez, Catherine Blanc, et al.. (2022). A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity. Mucosal Immunology. 15(6). 1389–1404. 7 indexed citations

Lopez, Jodie, Kirill Nemirov, Catherine Blanc, et al.. (2022). An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy. 30(9). 2984–2997. 19 indexed citations

10.

Anna, François, Joël LeMaoult, Philippe Souque, et al.. (2021). First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G. Journal for ImmunoTherapy of Cancer. 9(3). e001998–e001998. 34 indexed citations

11.

Moyon, Quentin, Delphine Sterlin, Makoto Miyara, et al.. (2021). BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 81(4). 575–583. 50 indexed citations

12.

Wu, Ching‐Lien, Julien Caumartin, Giada Amodio, et al.. (2021). Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC. Frontiers in Immunology. 11. 608614–608614. 11 indexed citations

13.

Dufloo, Jérémy, Ludivine Grzelak, Isabelle Staropoli, et al.. (2021). Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. Cell Reports Medicine. 2(5). 100275–100275. 42 indexed citations

14.

Roederer, Thomas, Bastien Mollo, Birgit Nikolay, et al.. (2021). Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study. The Lancet Public Health. 6(4). e202–e209. 73 indexed citations

15.

Anna, François, Maxime Fredon, Francine Garnache‐Ottou, et al.. (2021). Promoter’s Choice Drive CAR-T Efficiency. 4(3). 2 indexed citations

16.

Anna, François, Philippe Souque, Stéphane Pêtres, et al.. (2020). A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus. Molecular Therapy. 28(8). 1772–1782. 20 indexed citations

17.

Anna, François, et al.. (2020). HLA-G Neo-Expression on Tumors. Frontiers in Immunology. 11. 1685–1685. 53 indexed citations

18.

Mathian, Alexis, Delphine Sterlin, Makoto Miyara, et al.. (2020). Les Immunoglobulines A dominent la réponse anticorps neutralisante précoce anti-SARS-CoV-2. La Revue de Médecine Interne. 41. A63–A64. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact